Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants - Scorecard - MDSpire

Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants

  • By

  • Ching-Hsuan Hsu

  • Ting-Yi Chang

  • Ya-Min Chang

  • Shin-Han Lin

  • Tzu-Ning Chen

  • Keng-Hao Hsu

  • Jhong-Jhe You

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Creation of bispecific antibodies exhibiting improved neutralization efficacy against various SARS-CoV-2 Omicron subvariants

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingSpecify clinical applications for bispecific antibodies.

Key Highlights

  • add_data

Guideline-Based Recommendations

Diagnosis

    Management

    • D
    • e
    • t
    • a
    • i
    • l
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • m
    • a
    • n
    • a
    • g
    • e
    • m
    • e
    • n
    • t
    • s
    • t
    • r
    • a
    • t
    • e
    • g
    • i
    • e
    • s
    • f
    • o
    • r
    • b
    • i
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • a
    • n
    • t
    • i
    • b
    • o
    • d
    • i
    • e
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • expand_rationale

        Related Resources & Content

        Original Source(s)

        Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants

        • by Ching-Hsuan Hsu, Ting-Yi Chang, Ya-Min Chang, Shin-Han Lin, Tzu-Ning Chen, Keng-Hao Hsu, Jhong-Jhe You

        • June 17, 2026

        Related Content

        Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

        Longitudinal trajectories of hematological indices and serum metalloproteinases-2 and 9 over 1 year after moderate and severe COVID-19

        When Bad Data Enters the Drug Pipeline

        Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.